Drug intelligence / Profile preview

corn oligopeptide

Development stage
Unknown
Lead developer
Ningbo Green-Health Pharmaceutical
Modality
Peptides
Administration
Oral, Topical
01

Overview

Corn oligopeptide (COP) is a bioactive peptide mixture derived from corn gluten meal or zein proteins through enzymatic hydrolysis. It is primarily composed of small peptides with molecular weights under 1000 Daltons, which facilitates high water solubility and rapid absorption by the human body. COP exhibits several biological activities, most notably the inhibition of angiotensin-converting enzyme (ACE), which mediates antihypertensive effects by reducing vascular tone and angiotensin production. Additionally, it modulates the Sirtuin and Akt/NF-κB signaling pathways, contributing to its antioxidant, anti-inflammatory, and hepatoprotective properties. COP has been studied for its potential in managing nonalcoholic fatty liver disease (NAFLD), hepatic fibrosis, cirrhosis, and alcohol-induced liver damage, and has been evaluated in clinical trials as a nutritional support for post-surgical liver cancer patients. It is typically categorized as a functional food ingredient or nutraceutical rather than a conventional pharmaceutical drug.

Other names
corn oligopeptidesCOPCOPscorn gluten meal hydrolysate
02

Targets

AKT (RAC-alpha serine/threonine-protein kinase)ACE (Angiotensin Converting Enzyme)NF-κBSIRT (Sirtuin family)

Beyond the preview

Go deeper on corn oligopeptide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on corn oligopeptide.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call